Alzheimer’s Disease Research Request for Proposals
Alzheimer’s Disease Research, a BrightFocus Foundation program, provides research funds for U.S. domestic and international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of Alzheimer’s disease.
We are committed to supporting scientists from diverse backgrounds to foster creativity and innovation in addressing complex scientific challenges and strongly encourage applications from individuals who are from groups underrepresented in Alzheimer’s disease research.
FY26 Dates & Deadlines
Request for Proposals Opens
June 30, 2025
Full Proposals Due
September 29, 2025
All deadlines are 5:00 p.m. EST (Washington, D.C.) on the day of the deadline.
Program Update:
Please note that a Letter of Intent is no longer required for this program. Applicants must submit a full proposal by the stated deadline.
About the Awards
Alzheimer’s Disease Research offers two types of awards:
Standard Awards
This research grant program is restricted to new and early investigators who have obtained their MD, PhD, or equivalent degree within the past 12 years at the time of application. The applicant must serve as the principal investigator on the project, have institutional permission to manage the award and the key personnel associated with the proposal.
- Award Amount: $300,000
- Duration: 3 years
Postdoctoral Fellowship Awards
Must be within 5 years of degree conferral.
Postdoctoral fellowship awards are intended for young researchers in their final stages of mentored training. These awards fund projects in an established laboratory that will serve as the basis for the applicant’s independent research career.
- Award Amount: $200,000
- Duration: 2 years
Related News
New Blood Test Could Personalize Alzheimer’s Treatment Like Never Before
A new Alzheimer’s blood test may reveal how far the disease has progressed and identify who’s most likely to benefit from anti-amyloid therapies.
What Early-Life Brain Activity May Reveal About Alzheimer’s Risk
BrightFocus Alzheimer’s Disease Research grant recipient Keith Hengen, PhD, is pioneering a novel approach to identifying Alzheimer’s risk in early life, which could enable earlier diagnosis, risk reduction, and treatment.
FDA Clears First Blood Test to Aid in Alzheimer’s Diagnosis
The Lumipulse G β-Amyloid Ratio (1-42/1-40) blood test, manufactured by Fujirebio Diagnostics, measures two forms of amyloid-beta in the blood.
Does Disrupting the Brain’s Clock Influence Alzheimer’s?
An Alzheimer’s Disease Research-funded researcher is investigating the link between circadian rhythm disruption by jet lag and Alzheimer’s in the hopes of finding new treatment targets.
Breaking News Dispatch: Alzheimer’s Drug Breakthroughs and Care Access Tools
Read the top headlines in Alzheimer’s clinical trials and healthcare platforms.
A BrightFocus-Funded Non-Invasive Treatment Slows Alzheimer’s Progression in Yearlong Study
Sinaptica Therapeutics unveils breakthrough Phase 2 results for an experimental non-invasive treatment for Alzheimer’s disease.
Breaking News Dispatch: A Non-Invasive Alzheimer’s Treatment, Early Detection, and More
Get the latest in Alzheimer’s screening and treatments.
Could Finding and Treating Tiny Blood Clots in the Brain Delay Alzheimer’s?
A BrightFocus-funded scientist is investigating a novel imaging tool that could be used to find treatable blood clots in the brain and slow the progression of Alzheimer’s disease.
BrightFocus Workshop Helps Shape Future Alzheimer’s Leaders
Students and senior Alzheimer’s researchers gathered in Chicago for an immersive workshop hosted by BrightFocus Foundation.